Chai Ming G, Kim-Fuchs Corina, Angst Eliane, Sloan Erica K
Monash Institute of Pharmaceutical Sciences, Monash University.
J Vis Exp. 2013 Jun 28(76):50395. doi: 10.3791/50395.
Pancreatic cancer has an extremely poor five-year survival rate of 4-6%. New therapeutic options are critically needed and depend on improved understanding of pancreatic cancer biology. To better understand the interaction of cancer cells with the pancreatic microenvironment, we demonstrate an orthotopic model of pancreatic cancer that permits non-invasive monitoring of cancer progression. Luciferase-tagged pancreatic cancer cells are resuspended in Matrigel and delivered into the pancreatic tail during laparotomy. Matrigel solidifies at body temperature to prevent leakage of cancer cells during injection. Primary tumor growth and metastasis to distant organs are monitored following injection of the luciferase substrate luciferin, using in vivo imaging of bioluminescence emission from the cancer cells. In vivo imaging also may be used to track primary tumor recurrence after resection. This orthotopic model is suited to both syngeneic and xenograft models and may be used in pre-clinical trials to investigate the impact of novel anti-cancer therapeutics on the growth of the primary pancreatic tumor and metastasis.
胰腺癌的五年生存率极低，仅为4%至6%。迫切需要新的治疗方案，这依赖于对胰腺癌生物学有更深入的了解。为了更好地理解癌细胞与胰腺微环境的相互作用，我们展示了一种胰腺癌原位模型，该模型允许对癌症进展进行非侵入性监测。将荧光素酶标记的胰腺癌细胞重悬于基质胶中，并在剖腹手术期间注入胰腺尾部。基质胶在体温下凝固，以防止注射过程中癌细胞泄漏。注射荧光素酶底物荧光素后，利用癌细胞生物发光发射的体内成像监测原发性肿瘤的生长以及向远处器官的转移。体内成像还可用于跟踪切除术后原发性肿瘤的复发情况。这种原位模型适用于同基因和异种移植模型，可用于临床前试验，以研究新型抗癌疗法对原发性胰腺肿瘤生长和转移的影响。
